Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 19/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | TPO | P07202 | 15/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461751 | 0.83 | MPO (0.42) | MPOOPRM1TPOCYP3A4 | |
| Verdiperstat SCHEMBL1536607 | 0.77 | MPO (1.00) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL28896567 | 0.76 | MPO (0.65) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL4257613 | 0.75 | MPO (0.64) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL1536701 | 0.73 | MPO (0.64) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL34461750 | 0.73 | ADORA2A (0.38) | MPOOPRM1 | |
| SCHEMBL34461757 | 0.71 | ADORA2A (0.62) | — | |
| SCHEMBL1536647 | 0.70 | MPO (0.52) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL30028986 | 0.70 | MPO (0.59) | MPOOPRM1TPOCYP3A4KCNH2 | |
| SCHEMBL30601263 | 0.69 | MPO (0.67) | MPOOPRM1TPOCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-2029603-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE AS MYELOPEROXIDASE INHIBITOR | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007142577-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVE AS MYELOPEROXIDASE INHIBITOR | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124640-A1 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor | MPO, CAT, GPX1 | MPO 1/4885OPRM1 1579/4885TPO 16/4885 |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | MPO 3248/4885OPRM1 2999/4885TPO 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.